Pregled bibliografske jedinice broj: 1128086
The process of urinary bladder cancer recurrence in 33 patients with 113 tumors, analyzed by changes in IHC features of 80 pairs of subsequent tumors
The process of urinary bladder cancer recurrence in 33 patients with 113 tumors, analyzed by changes in IHC features of 80 pairs of subsequent tumors // ASCO Meeting Library. J Clin Oncol 39, 2021 (suppl 15 ; abstr e16507)
Alexandria (VA): American Society of Clinical Oncology, 2021. e16507, 2 doi:10.1200/JCO.2021.39.15_suppl.e16507 (ostalo, međunarodna recenzija, prošireni sažetak, znanstveni)
CROSBI ID: 1128086 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
The process of urinary bladder cancer
recurrence in 33 patients with 113 tumors,
analyzed by changes in IHC features of 80 pairs
of subsequent tumors
(The process of urinary bladder cancer
recurrence in 33 patients with 113 tumors,
analyzed by changes in IHC features of 80 pairs
of subsequent tumors.)
Autori
Kurbel, Sven ; Dmitrović, Branko ; Matić, Mate ; Vrbanec, Damir
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, prošireni sažetak, znanstveni
Izvornik
ASCO Meeting Library. J Clin Oncol 39, 2021 (suppl 15 ; abstr e16507)
/ - Alexandria (VA) : American Society of Clinical Oncology, 2021
Skup
Annual Meeting (ASCO 2021)
Mjesto i datum
Chicago (IL), Sjedinjene Američke Države, 04.06.2021. - 08.06.2021
Vrsta sudjelovanja
Ostalo
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
bladder cancer, reccurent disease, Ki-67 antigen
Sažetak
Background: The aim was to define IHC changes between the two subsequent urinary bladder cancers (UBC). Methods: IHC data on EGFR, HER2, HER3, Ki- 67, MLH1, MSH2, MSH6 and PMS2 in 113 UHC from 24 male and 9 female patients (1 to six recurrences) were used. Except for the Ki-67 value, other markers were stratified: “0” for no positive cells ; “1” <= 10% positive cells ; “2” 1%-30% positive cells ; and “3” 31%-100% positive cells. Data of consecutive tumors were paired in 80 processes of recurrence (PoR). Changes between the latter and the former tumor were calculated: in +/- % for Ki- 67 values, and as integer sums of absolute changes in expression for HER markers and for Lynch markers. EM clustering was applied for recognition of relevant IHC changes. Results: Three aspects were tested: the speed of recurrence, was it the first, or later recurrence and whether PoRs depended on the total number of tumors in that patient. Early and late PoRs clustered along the Lynch score, while the intermediate clustered along the delta Ki-67 value. The first PoRs clustered along the HER score and all subsequent PoRs depended on the Lynch score. Conclusions: Even in this limited group of patients Lynch and HER markers showed complex differences between early and late recurrent tumors. The speed of the recurrence and changes of IHC features depended mainly on the rate of change in Lynch markers, suggesting that they should be tested as predictors of UBC recurrence. Research Funding: VIF2018-MEFOS-02
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
VLASTITA-SREDSTVA-VIF2018-MEFOS-02 - Prediktivnost značajki imunohistokemijskog fenotipa raka mokraćnog mjehura u pojavnosti ranih i kasnih recidiva kao pokazatelja biologije tumora (Kurbel, Sven, VLASTITA-SREDSTVA ) ( CroRIS)
Ustanove:
Medicinski fakultet, Osijek,
Sveučilište Jurja Dobrile u Puli,
Fakultet za dentalnu medicinu i zdravstvo, Osijek
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE